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IN1
C.ALBICANS AND C. GLABRATA BLOODSTREAM
INFECTIONS IN ADULTS: OUTCOMES AND ASSOCIATED
COSTS
Grussemeyer CA1, Friedman JY1, Spalding JR2, Benjamin DK3,
Moran C3, Reed SD1
1Duke Clinical Research Institute, Durham, NC, USA, 2Astellas Pharma
US, Deerﬁeld, IL, USA, 3Duke University Medical Center, Durham,
NC, USA
OBJECTIVE: Mortality and economic consequences associated
with Candida bloodstream infections are considerable, and the
incidence of Candida glabrata infections is increasing. This
investigation aimed to evaluate inpatient costs, length of stay
(LOS), and mortality associated with candidemia in adults 18
years, focusing on differences between Candida glabrata and
Candida albicans. METHODS: The study cohort consisted of all
patients hospitalized at Duke University Medical Center from
February 1996 to July 2007 with a blood culture positive for
C. glabrata or C. albicans. Patients were stratiﬁed according to
whether their ﬁrst positive culture occurred within the ﬁrst two
days of hospital admission or thereafter. Detailed cost account-
ing data were available since December 2002. Generalized linear
models using gamma distributions and log links were used to
compare costs, negative binomial models for LOS, and chi-
square tests for inpatient mortality. RESULTS: A total of 241
adults with C. glabrata and 402 adults with C. albicans blood-
stream infections were identiﬁed. Complete data on LOS was
available for 99.1% and cost data for 38.1%. Approximately
20% of patients had a positive blood culture within the ﬁrst two
days of admission (C. glabrata, 18.7%; C. albicans, 21.1%).
Among these patients, those with C. glabrata versus C. albicans
had longer LOS (19.7 days vs. 14.2 days, p = 0.03), higher costs
($56,026 vs. $31,168, p = 0.02), and comparable mortality rates
(33.3% vs. 35.3%, p = 0.82). Among patients in whom the ﬁrst
positive blood culture occurred later, LOS (22.0 days vs. 20.1
days, p = 0.29), costs ($68,280 vs. $51,688, p = 0.06) and inpa-
tient mortality (48.5% vs. 44.8%, p = 0.42) were more similar.
CONCLUSION: Candida bloodstream infections in adult
patients are associated with substantial costs, long LOS, and
high mortality rates. Unadjusted comparisons revealed longer
inpatient stays and higher costs among patients with early
evidence of bloodstream infection with C. glabrata relative to
C. albicans.
IN2
UPPER RESPIRATORY ILLNESS AND EMPLOYEE
PRODUCTIVITY—RESULTS FROMTHE CHILD AND
HOUSEHOLD INFLUENZA-ILLNESS AND EMPLOYEE
FUNCTION (CHIEF)
Palmer L1, Nichol KL2, Johnston S1, Mahadevia PJ3, Rousculp MD3
1Thomson Healthcare, Inc,Washington, DC, USA, 2Veterans Affairs
Medical Center, Minneapolis, MN, USA, 3MedImmune, Inc,
Gaithersburg, MD, USA
OBJECTIVE: Evaluate the effect of pediatric and household
upper respiratory illness/common cold (URI) on employee func-
tion. METHODS: The CHIEF Study is a prospective cohort
study of 2295 United States employees with children among
three large Fortune 500 companies. Prospective monthly survey
responses are collected during the 2007–2008 inﬂuenza season
and linked to an administrative health care claims database. The
survey component asks employees about the effect of both per-
sonal and household member (HHM) illnesses/injuries and URI
on their absenteeism and presenteeism. The administrative claims
database component includes information about health care uti-
lization and expenditures. RESULTS: Initial monthly results indi-
cate that employees with URI (n = 680) reported more days of
absenteeism (0.53 vs. 0.44, respectively; p = 0.2453) and more
hours of presenteeism (0.88 hours vs. 0.38 hours, respectively;
p < 0.0001) than employees without URI (n = 1536). Employees
with at least one HHM experiencing URI reported missing more
days of work (0.17 vs. 0.06, respectively; p = 0.0016) and more
hours of presenteeism (0.43 and 0.14, respectively; p < 0.0001)
than employees reporting otherwise. Among employees reporting
URI, symptoms lasted 4.77 days on average—about half of
which were “most severe” (2.31 days). Employees also reported
that it took 6.20 days to “get back to normal” following
symptom onset. Employees reporting URI and any productivity
loss missed 1.36 days of work and experienced 2.79 hours of
presenteeism because of their symptoms. Productivity was also
negatively affected for employees with at least one HHM expe-
riencing URI—employees reported missing 1.25 days of work
and having 0.56 hours of presenteeism as a result of HHM
symptoms. CONCLUSION: Employees are signiﬁcantly less
productive—in terms of both absenteeism and presenteeism—
when they have URI symptoms. Furthermore, employee produc-
tivity is also signiﬁcantly impacted when a HHM reports URI
symptoms.
IN3
A MICROSIMULATION OFTHE COST-EFFECTIVENESS
OF MARAVIROC FOR ANTIRETROVIRAL
TREATMENT-EXPERIENCED HIV-INFECTED INDIVIDUALS
Chancellor JV1, Kuehne FC2, Mollon P3, Louie M4, Powderly WG5
1i3 Innovus, Uxbridge, Middlesex, UK, 2PharmacoConsult,
Wanzleben-Buch, Germany, 3Pﬁzer Limited, Sandwich, Kent, UK, 4Pﬁzer
Inc, New York, NY, USA, 5University College Dublin, Dublin, Ireland
OBJECTIVE: Maraviroc (MVC) is a CCR5 co-receptor antago-
nist indicated for combination antiretroviral treatment of adults
infected with only CCR5-tropic HIV-1 detectable, who have
evidence of viral replication and HIV-1 strains resistant to mul-
tiple antiretroviral agents. The cost-effectiveness of a strategy of
testing and treating with optimized background therapy (OBT),
MVC according to tropism test results, compared to treating
with OBT alone, was modeled from a US payers’ perspective
using 48-week MOTIVATE-1 and -2 trial endpoints.
METHODS: The MOTIVATE screening cohort (mean age:
45 years, male: 86%, mean baseline CD4: 184 cells/mL, mean
baseline HIV-1 RNA: 4.72 log10 copies/mL, CCR5-monotropic:
51%, history of opportunistic infections: 67%) was microsimu-
lated using the previously reported ARAMIS model. To achieve
convergence, the cohort was sampled 200,000 times with
replacement. MVC cost $29/day, tropism testing cost $1960,
and care costs were taken from HIV Research Network data.
Utilities were based on a published US survey. RESULTS: In the
MOTIVATE trials, 56.1% of patients receiving MVC + OBT
and 22.5% receiving OBT alone were virologically suppressed
to <400 copies/mL at 48 weeks. Projecting observed virologic
failure rates linearly, ARAMIS predicted life expectancy of 94.5
and 88.9 months for the OBT MVC and OBT strategies,
respectively. Mean QALYs and lifetime costs per patient were
5.03 and $236,900 for OBT MVC and 4.75 and $220,400
for OBT, for an incremental cost-effectiveness ratio (ICER) of
$60,100 per QALY gained ($55,000–$62,600 over 95% CI for
MVC + OBT suppression). Varying the proportion of CCR5-
monotropic individuals from 30%–80% gave ICERs from
$65,500–$56,400. For patients with HIV susceptible to 2
drugs, life expectancy for OBT MVC and OBT alone was
92.5 and 85.5 months respectively, giving an ICER of $55,400.
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